GRAIL has entered an agreement with Quest Diagnostics to provide phlebotomy services in support of its multi-cancer early detection blood test.
The test, called Galleri, is expected to go to market in the second quarter after its PATHFINDER multi-site interventional study.
Under the agreement, Quest’s phlebotomy network, which is composed of approximately 2,200 patient service centers and 5,000 mobile phlebotomists, will help GRAIL with its specimen collection when Galleri is launched.
“Today, the majority of cancers go undetected until too late when outcomes are often deadly, and we believe Galleri could offer a unique and potentially life-saving solution by finding multiple types of cancers earlier,” said GRAIL Chief Medical Officer and Head of External Affairs Joshua Ofman. “Our agreement with Quest will help us support convenient access to blood collection for patients and healthcare providers.”
“Quest Diagnostics is committed to providing the broadest access to diagnostic innovation,” said Kristi Dolan, VP and general manager of Quest’s oncology clinical franchise. “Galleri is a pioneer in early detection innovation, and we are eager to support GRAIL’s efforts to make it accessible to patients across the United States.”
Read the original story here.